Treatment protocol
MRD, PML
RESIDUAL DISEASE, PROMYELOCYTIC LEUKEMIA, PML
Patients were treated with a risk-adapted protocol (Suppl. Table Measurable residual disease (MRD) monitoring of bone marrow was performed by Quantitative reverse-transcription PCR (qRT-PCR) for PML/PARα (the fusion of promyelocytic leukemia (PML) gene and retinoic acid receptor alpha (RARA) genes) at the end of induction, before the beginning of maintenance, and every 24 weeks from the beginning of maintenance to 48 weeks after the end of maintenance (Suppl. Table 